VitaSeno by Aubrai

The global market for senolytic therapies is poised for rapid expansion as the burden of age-related diseases rises alongside an aging population. Senolytic drugs, which selectively eliminate senescent cells, have the potential to address a broad spectrum of age-associated conditions, as cellular senescence contributes to chronic inflammation, tissue dysfunction, and pathologies ranging from osteoarthritis and cardiovascular disease to oncology and neurodegeneration. This positions senolytics as a multibillion-dollar opportunity across multiple therapeutic areas. Value will be captured through proprietary identification of highly selective, novel targets and drug candidates, enabling the development of disease-modifying therapies that shift treatment paradigms from symptom management to root-cause intervention. By improving patient outcomes, reducing long-term healthcare expenditures, and enhancing quality of life, the project aligns with significant unmet clinical needs and emerging opportunities in the longevity and regenerative medicine markets.